HP Inc.: For the three- and nine-month periods ended July 31, 2026, the company received $127m in tariff refunds; an additional $91m was received after the reporting period.

SC crude front-month contract continued higher, up over 2.00% intraday and trading at 575.80 yuan/barrel.

The FDA has approved Revolution Medicines' pancreatic cancer drug Daraxonrasib, which will be marketed as Rasonque. The drug is the first therapy targeting one of the disease's key molecular pathogenic mechanisms. A late-stage trial published in May showed Daraxonrasib nearly doubled typical survival in an aggressive form of pancreatic cancer to 13.2 months versus 6.7 months with chemotherapy, the current standard of care.